Treatment of patients with myeloma has changed dramatically in the past years due to development of new agents and myeloma-specific targets. Despite these advancements, long-term benefit remains less clear in high-risk multiple myeloma patients. Myeloma is classified as high-risk based on presence of cytogenetic abnormalities and poor treatment outcomes. We are talking to Dr. Parameswaran Hari on his recent research on post-transplant outcomes in high risk myeloma patients.
Dr. Parameswaran Hari is the Clinical Director of the Adult Bone Marrow Transplant Program and Associate Professor of Medicine, Division of Hematology and Oncology at the Medical College of Wisconsin. According to myelomasurvival.com, Dr. Hari has the best 2 and 3 year survival rates for myeloma patients. Myeloma patients under Dr. Hari's care at the Medical College of Wisconsin are 13 times more likely to survive 2 years and 7.2 times more likely to survive 3 years than in an average SEER facility. The SEER(Surveillance, Epidemiology and End Results) data from the National Cancer Institute provides survival data for many cancers including multiple myeloma.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register